Biocartis launches partnership in liquid biopsy

Belgian liquid biopsy specialist Biocartis Group NV has announced it will co-develop a breast cancer assay with MRC Technology.

Read more

The Difference of One Simple Sort

One researcher, one sorter, one cell, many discoveries. BD is dedicated to developing easy-to-use cell sorting technologies that simplify accurate and reliable flow cytometry.

Read more

Biomanufacturing: Why single-use?

Established in 2013, Polpharma Biologics is the biotechnology unit of the rapidly growing ­Polpharma Group one of the largest pharmaceutical players in the CEE region. Currently, with over 140 people, four sites, and full expertise for biopharmaceutical development and production, Polpharma Bio­logics is running five projects dedicated to monoclonal antibodies, and is just stepping into the contract development and manufacturing business.
Read more

Pharmalink: Launching into Phase III

Pharmalink AB has hired Renee Aguiar-Lucander as Chief Executive Officer. She will lead the expansion and strategic development of the Swedish specialty pharmaceutical company following the clinical success of its orphan drug Nefecon.
Read more

Merck KGaA and F-star in €1bn deal

German Merck KGaA has secured an option on UK’s F-Star Biotechnology Ltd’s preclinical bispecific PD-L1/LAG checkpoint inhibitor FS118 and four candidates in discovery stage.

Read more

Metrion Biosciences: Developing the business

Cambridge-based specialist ion channel CRO and drug discovery company Metrion Biosciences Ltd has named James Beaumont Head of Business Development. He joins from NZP-Dextra, where he held the post of Development Director.
Read more

Bicycle raises £40m

Cambridge-based cancer company Bicycle Therapeutics has raised £40m to advance its clinical pipeline of peptide-based conjugates with antibody-like binding properties. 

Read more

EC and EMA provide Brexit guidance

UK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch release to a location established in the Union.

Read more

Addex further improves liquidity

Following a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinson’s and ADX71441.

Read more

Gyros Protein Technologies: European Marketing

Gyros Protein Technologies has appointed Mark Vossenaar as Vice President, European Sales.

Read more